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Abstract
Core needle biopsy (CNB) is considered to have similar results with open biopsy in accuracy and already 
becomes a routine procedure to establish the diagnosis of musculoskeletal lesion. However, the accuracy of CNB 
for muskuloskeletal lesion in Indonesia has not been reported. The aims of the study to know the accuracy of 
CNB for muskuloskeletal tumor diagnoses. From January 2011 to August 2015, all patients with musculoskeletal 
lesion in dr. Cipto Mangunkusumo Hospital underwent CNB and subsequently, tumour excision were indentified 
and enrolled. Diagnostic accuracy was evaluated for both histopathology and clinicopathological conference 
(CPC) conclusion. A total of 86 samples were enrolled in this study. The accuracy of CNB compared to post 
excision histopathology is 74.4%. With CPC conclusion, the accuracy is 83.7% with sensitivity 98%, specificity 
59% (p<0.001). The accuracy of CNB after immunohistochemistry was increased from 74.4% to 84.9% with 
sensitivity 98%. The accuracy of CNB was 97.1% and 82.7% for benign lesion and malignant lesion respectively 
(p<0.01). The accuracy of CNB to differ and to confirm diagnosis as primary or metastatic lesion was 97.2% and 
85.7% respectively (p<0.001). Inconclusion, CNB is a reliable diagnostic method to establish musculoskeletal 
tumor diagnoses. CPC significantly provides better accuracy rate of CNB. 
Keywords: core needle biopsy, musculoskeletal lesion, clinical pathology conference
Akurasi Biopsi Jarum Inti untuk Mendiagnosis Lesi Muskuloskeletal di 
Rumah sakit Cipto mangunkusumo, Jakarta
Abstrak
Biopsi jarum inti dianggap memiliki akurasi yang sama dengan biopsi terbuka dan menjadi prosedur rutin 
untuk menegakkan diagnosis lesi muskuloskeletal. Meskipun demikian, belum ada laporan akurasi penggunaan 
biopsi jarum inti untuk lesi muskuloskeletal di Indonesia. Tujuan studi ini adalah mendapatkan nilai ketepatan 
diagnosis biopsi jarum inti pada lesi muskuloskeletal. Dari bulan Januari 2011 hingga Agustus 2015, semua 
pasien dengan lesi muskuloskeletal di RS dr. Cipto Mangunkusumo menjalani biopsi jarum inti, dilanjutkan 
dengan eksisi tumor dan identifikasi. Akurasi diagnostik dihitung dengan membandingkan histopatologi biopsi 
jarum inti dengan histopatologi pasca eksisi tumor dan didiskusikan sebagai hasil akhir histopatologi pada clinico-
pathological conference (CPC). Sebanyak 86 sampel diikutsertakan dalam penelitian ini. Perbandingan akurasi 
biopsi jarum inti dengan eksisi tumor adalah 74,4%. Dengan kesimpulan CPC, akurasi biopsi jarum inti 83,7% 
dengan sensitivitas 98%, spesifisitas 59% (p<0,001). Akurasi setelah pemeriksaan dengan imunohistokimia 
meningkat menjadi 84,9% dengan sensitivitas 98%. Akurasi untuk membedakan lesi jinak adalah 97,1% dan 
lesi ganas 82,7% (p<0,001). Akurasi dalam membedakan lesi primer adalah 97,2% dan lesi metastasis 85,7% 
(p<0,001). Biopsi jarum inti adalah metode biopsi yang dapat dipercaya, karena memberikan akurasi diagnosis 
tumor muskuloskeletal yang kurang lebih sama dengan biopsi terbuka. Untuk memperoleh hasil yang lebih baik 
hasil biopsi jarum inti harus dibicarakan dalam CPC dan dilakukan pemeriksaan imunohistokimia sesuai indikasi. 
Disimpulkan biopsi jarum inti memberikan hasil yang dipercaya untuk mendiagnosis lesi muskuloskeletal. CPC 
meningkatkan akurasi biopsi jarum inti pada lesi muskuloskeletal.
Kata kunci: biopsi jarum inti, lesi muskuloskeletal, clinico-pathological conference
 Core Needle Biopsy for Musculoskeletal Lesion
9
Vol. 4, No. 1, April 2016
Introduction
Open biopsy has long been regarded as 
the gold standard for establishing diagnosis of 
musculoskeletal lesions.1-3 However, recent studies 
show that core needle biopsy (CNB) has a similar 
diagnostic accuracy with open biopsy. The accuracy 
of CNB compared with open biopsy is ranging 
from 70% to 99%, because of the improvement 
in biopsy and histopathological techniques.4-7 In 
comparison to open biopsy, the CNB procedure 
is faster, less invasive, less expensive, more 
comfortable for the patient, and has a lower risk 
of morbidity and infection, and also prevents the 
spreading of malignant cells.4,7-8 Therefore, many 
studies have recommended CNB to establish 
musculoskeletal tumor diagnosis. In addition, some 
centers in the world mentioned that CNB as their 
standard procedure was sufficient to confirm final 
diagnosis.4,5,7-10
The CNB has been used as a diagnostic tool 
in dr. Cipto Mangunkusumo National Hospital 
(CMNH) since 2011, to be confirmed in the 
clinicopathological conference (CPC), for final 
diagnosis. Accuracy rate of CNB for diagnosis of 
musculoskeletal tumors in CMH and Indonesia 
has not been reported. Therefore, the study about 
accuracy of CNB compared with final surgical 
specimen (histopathologic diagnosis of post-
excisional tumor) needs to be done.
Methods
This study was a descriptive analytical study 
with cross-sectional design. Materials used were 
secondary data obtained from medical records in 
CMH from January 2011 to August 2015 including 
oncology registry book of the Department of 
Orthopaedic and Traumatology as well as data 
from Department of Anatomic Pathology. The final 
diagnosis which was not classified by international 
classification disease for oncology (ICD-O) from 
the WHO or ICD-10 were excluded.
CNB was conducted by two experienced 
orthopaedic surgeons using semi automatic cutting 
needle size 14. The needle was inserted from one 
point in the skin into intra-tumoral tissue in multiple 
directions. We took a minimum of five tissue 
samples which were directly fixed with  formalin 
10% to be further examined based on haematoxylin 
and eosin staining standard.
Lesion that needs computed tomography (CT) 
guide is usually due to its difficult location or  small 
lesion such as pelvic and sacral bone tumors. The 
CT guided CNB was conducted also by similar 
orthopaedic surgeon in Radiology Department 
CMH. Should an immuno-histochemical staining 
was necessary to confirm diagnosis, it might 
be performed upon decision during the CPC 
forum not by the decision of an expert. Every 
musculoskeletal tumor diagnosis should be 
discussed and established among orthopaedic 
surgeon, radiologist, and pathologist as the main 
participants of CPC.
Dependent variable in this study was 
histopathologic diagnosis of post-excisional 
specimen (control). Meanwhile, independent 
variables were CNB histopathology and CPC 
diagnosis of  CNB. External variables including 
immunohistochemical expression, type of the 
tumor, radiological expertise, primary or metastatic 
lesions, and size of lesion  were also analyzed. 
All collected data were analyzed using the SPSS 
program and Fisher’s exact test with a confidence 
level of 95%. P<0.05 was considered as statistically 
significant.
Results
 There were 86 musculoskeletal tumor patients 
who had both CNB and definitive surgery /excision 
in CMH within a period of 5 years from January 
2011 to August 2015.  Final diagnosis from all those 
cases can be classified based on ICD O or ICD-10 
classification. Thus, they were included as study 
subject. The age distributions were divided into 7 
groups: 0-10 year old 6 patients (pts), 11-20 yo 19 
pts, 21-30 yo 8 pts, 31-40 yo 13 pts, 41-50 yo 15 
pts,  51-60 yo 12 pts, and > 61 yo 13 pts.
 Final histopathologic diagnoses of post-
excisional specimen were divided into primary 
bone tumor, primary soft tissue tumor, metastatic 
lesions and other lesions. Thereafter, they were 
also divided into benign and malignant lesions as 
described in table 1.
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Table 1. Final Histopathological Diagnosis of Post-excision of 
Musculoskeletal Lesions 
Type of Lesion Malignant Benign
Primary Bone Tumor
Fibrous dysplasia
Benign fibrous of histiocytoma
Convensional osteosarcoma
Chondroblastic osteosarcoma
Small cell osteosarcoma
Periosteal osteosarcoma
Chondroma
Chondrosarcoma
Chondroblastoma
Chondromixoid fibroma
GCT
GCT sarcoma
Ewing’s sarcoma
Osteofibrous displasia
Chondroma
Neurofibromatosis
MPNST
Alveolar soft part sarcoma
Lymphoma
Plasmacytoma
Multiple myeloma 
Langerhans cell histiocytosis
Total
3
5
1
1
3
1
2
2
1
1
5
4
1
30
1
1
2
3
2
10
1
1
1
22
Primary Soft Tissue Tumor
Squamosa cell carsinoma
Fibroma
Rhabdomiosarcoma
Synoviosarcoma
Angiomatosis
Neurofibromatosis
Alveolar soft part sarcoma
Total
1
4
2
1
8
2
3
1
6
Metastasis Lesions
MBD epithelial
MBD SSC
MBD adenocarsinoma
MBD hepatocellular
Total
4
1
7
2
14
Others
Callus
Xantomatosis
Osteomyelitis
Ganglion cyst
Total
1
2
2
1
6
Total 52 34
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The accuracy rate of CNB for musculoskeletal 
lesion compared to post-excision specimen (control) 
is 74.4%. There was an increase in accuracy rate 
of CNB from 40% in 2011 up to 94.7% in 2015 
(Figure 1). 
Figure 1. Increased in  Accuracy of CNB for Musculoskeletal Tumor Diagnosis 
The accuracy rate of CNB after CPC was 
significantly further increase from 74% to 83.7% 
(sensitivity 98%, p<0.001). The result of specifity 
and sensitivity of core biopsy before and after 
CPC compared with control was shown in table 
2.  There were 16 cases post CNB which needed 
further Immunohistochemical examination. The 
immunohistochemistry had improved the accuracy 
of CNB characterized by 9 of 16 cases achieved 
final diagnosis. The accuracy of CNB after 
immunohistochemistry was increased from 74.4% 
to 84.9% with sensitivity 98% (Table 3).
Table 2. Accuracy of Core Biopsy after CPC Compared with Post-Excision Histopathology 
Histopathology
Total Sensitivity Specificity PPV NPV LLR (+) LLR (-)
CPC Yes No
Yes 63 9 72 0.98 0.59 0.87 0.93 2.4 0.03l
No 1 13 14
Total 64 22 86
PPV: positive predictive value; NPV: negative predictive value; LLR (+): positive likelihood ratio; LLR (-): negative likelihood ratio
Table 3. Accuracy of CNB with Immunohistochemical Staining
After IHC Core Biopsy Total Sensitivity Specificity PPV NPV  LLR (+) LLR (-)
Yes No
Yes 9 7 16 0.98 0.59 0.87 0.93 2.4 0.03l
No 63 7 70
Total 72 14 86   
IHC: Immunohistochemistry 
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The accuracy of CNB was 97.1% and 82.7% 
for benign lesion and malignant lesion respectively. 
The CNB may distinguish between benign and 
malignant lesion significantly (p<0.001). After CPC 
had been done, the accuracy rate of CNB improved 
significantly from 82.7% to 90.4% (p<0.001) for 
malignant lesion. 
Based on the origin of tumor cells, there were 
72 patients who diagnosed with primary tumor and 
14 patients with metastatic lesion. The accuracy 
of CNB to differ and to confirm diagnosis as 
primary or metastatic lesion was 97.2% and 85.7% 
respectively (p<0.001). After the CPC, the accuracy 
rate was increased to 98.6% for primary tumor and 
92.9% for metastatic lesion. Overall CNB sensitivity 
to distinguish between primary and metastatic 
lesions was 97%.
In this study, 71 of 86 patients (82.6%) had 
bone lesions and 15 of 86 patients(17.4%) had soft 
tissue lesions. The accuracy rate of CNB to establish 
diagnoses of the bone lesions was higher than 
soft tissue lesions (77.5% versus 60%). However, 
after the CPC was conducted, the accuracy was 
increased for both lesions (84.5% versus 80%). 
Discussion
After undertaking clinical and radiological 
examinations, one has to decide whether or not a 
biopsy is indicated. If the tumour is clinically and 
radiologically identified as a benign lesion such as 
osteochondroma and non-ossifying fibroma, one 
could omit a biopsy. In other words, physician may 
observe  in some benign tumors or treated without 
prior biopsy.11-12
Management of bone and soft tissue tumors 
require high diagnostic accuracy due to the 
distinctive treatment in benign and malignant 
lesions. An accurate early diagnosis might lead 
an increase in patient’s prognosis and in CMH, 
a CPC remains the mainstay in diagnosing a 
musculoskeletal lesions.
There are two methods of biopsy including 
closed and open biopsies.1,12 Open biopsy is the  gold 
standard procedure to establish musculoskeletal 
tumor diagnosis2-4,12 and a reliable diagnostic method 
because it allows the pathologist to evaluate cellular 
morphologic features and tissue architecture from 
different sites of the lesion. Furthermore, it provides 
material for performing ancillary studies such as 
immunohistochemistry, cytogenetics, molecular 
genetics, flow cytometry, and electron microscopy. 
Those studies may help in the diagnosis and 
subclassification of bone and soft-tissue tumors, 
therefore guide the definitive treatment.13  
Open biopsy has some disadvantages and more 
potential hazards than closed biopsy technique. 
The open biopsy is more difficult so that it needs 
more experienced skill from surgeon. It is also more 
expensive and may cause haematoma, infection, 
more contamination to the surrounding tissue, and 
bone destruction. Haematoma and infection may 
lead to amputation of the limb.13-16
Closed biopsy technique consists of fine needle 
aspiration biopsy (FNAB) and CNB. Both FNAB and 
CNB are less invasive, fewer potential complications, 
less expensive and require less time to perform 
than open biopsy.1,4,7 The advantages of FNAB are 
that it could easily acquire sample material (cells) 
from different parts of large tumor and be rapidly 
stained to obtain a rapid diagnosis.14 Meanwhile, by 
means of CNB tissue sample architecture is more 
descriptive. An accurate yet easy to perform and less 
invasive biopsy procedure is required in diagnosing 
a musculoskeletal lesion. 1,13
Needle biopsy of mesenchymal tumors initially 
was criticized because the quantity of biopsy 
material was often insufficient for histopathologic 
evaluation and ancillary studies that require tissue. 
FNAB using a 22-gauge needle, is a reliable 
technique for the diagnosis of soft-tissue tumors 
that also provides sufficient material for additional 
studies.12,13
In CMH, CNB had been conducted commonly 
in patients who had musculoskeletal lesions (after 
completely clinical and radiological staging). It is 
also as diagnostic procedure of choice if FNAB 
failed to determine the final diagnosis or FNAB 
could not reach the lesions because of intact 
cortical bone or open biopsy is very difficult.13,17 
In this study, 86 cases of musculoskeletal 
lesion were performed core biopsy then confirmed 
with histopathology of post excision tissue as 
control and discussion in CPC. A number of 
74.4% cases with CNB technique were correctly 
diagnosed based on histopathological evaluation 
only. However, it was increased significantly upon 
CPC to 83.7% (p<0.001). 
Since we performed CNB for musculoskeletal 
lesion diagnostic approach 2011, there was a trend 
toward increasing in accuracy over time (from 40% in 
2011 up to 94.7% in 2015). The improved accuracy 
rate was mainly caused by better CNB technique 
(learning curve), experience of the pathologist 
to evaluate the small tissue samples from CNB, 
the more common use of immunohistochemical 
staining and deep discussion in CPC. This result is 
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consistent with two previous studies from Pohlig et 
al.2 and Sung et al.10  which were gaining accuracy 
of 84.6% and 84.3% respectively upon CPC.
      Around 28 of 86 patients (cases) which had 
the image-guided CNB (CT or fluoroscopy) render 
diagnostic accuracy of 85.7% (24/28 cases). That 
result is similar with Sung et al.10 study that reported 
accuracy rate of image guided CNB (ultrasound, 
CT or fluoroscopy) was 84.3%.  Heslin et al.18 
reported that CNB had more than 90% accurate in 
differentiating malignant from benign lesions. He 
recommended bone biopsies, using a CNB, should 
be performed under CT or fluoroscopy guidance, 
and multiple cores should be obtained. 
      In this study, CNB could significantly distinguish 
a benign and a malignant musculoskeletal lesion 
(p<0.001) with accuracy of 97.1% and 82.7%. 
which after a CPC were done was further increased 
significantly to 90.4% in distinguishing a malignant 
lesion. This result is similar to other studies ranging 
from 76% to 99%.5
Although examination of hematoxylin-
eosin staining is a gold standard for diagnosis of 
musculoskeletal tumor, immunohistochemistry 
remains an integral part of this process 
especially for soft tissue sarcomas. In this study, 
immunohistochemistry also provides better 
accuracy of CNB. Our result is consistent with 
Pringle19 who mentioned that immunohistochemistry 
plays a role to confirm a diagnosis of bone lesion, 
although it has some limitations.  In addition, final 
result should be discussed among the experts. 
In this study, CNB could significantly differ 
a primary bone tumor from metastatic lesion 
(97.2% and 85.7%). Should that result discussed 
in CPC, it was increased until 98.6% and 92.9% 
respectively. This result shows is similar to a study 
from Seng et al.20  They reported that the accuracy 
of CNB in detecting malignancy was 88%. Fraser-
Hill21 reported the accuracy rate of CNB 82% for 
metastatic lesion and 83% for primary lesion.
Accuracy rate of CNB in bone lesion is higher 
than soft tissue lesion (77.5% versus 60%). CPC 
always provides better accuracy rate of CNB 
thus, after discussing in CPC it could achieve 
84.5% and 80% for each lesion. However, Pohlig 
et al.2 and Sung et al.10  reported better results 
than us whether accuracy of CNB in bone lesion 
or soft tissue lesion. Almost studies reported 
that accuracy of histopathology of bone tumor 
was better than soft tissue tumor, although no 
statistically significant difference was found. Bone 
tumor had more pathognomonic cells than soft 
tissue tumor. Therefore, it is easier to diagnose and 
to differentiate bone tumor than soft tissue tumor 
which has much more variations. 1  
There were six unrepresentative CNB samples 
reducing the accuracy. It might be due to some 
factors the size and location lesion, the surgeon 
skills and the image-guided biopsy.8,17,18 However, 
there was no morbidity related to the procedure 
in our research. CNB  facilitates the planning of 
definitive surgery and neo-adjuvant chemotherapy 
and could be easily repeated or followed by an 
open biopsy without causing a major morbidity to 
the patient. It is a safe procedure by skilled persons 
which complication rate as low as less than 1%. 
 The indication of the CNB in this study was 
determined by orthopedic oncologist decision 
after considering the clinical data and radiologic 
investigations. There is no guideline of CNB 
indication yet in CMH previously however, some 
pathologists in CPC suggested to do CNB in case 
of FNAB was inconclusive of difficult to establish 
a certain diagnosis. McCharty22 suggested that 
CNB was performed after the discussion among 
orthopedic surgeon, pathologist, and radiologist. 
Although the analysis of CNB was carried out by a 
pathologist, clinical and radiologic data also could 
affect the histopathology conclusion. 
Commonly, histopathologic forms were not 
accompanied by sufficient clinical and radiologic 
informations, thus the histopathologic conclusion 
became blunt and affected the diagnostic accuracy 
test statistically. Significant of a clear clinical 
information related to final diagnosis should be 
further investigated.
Conclusion
CNB is a reliable diagnostic method to 
establish musculoskeletal tumor diagnoses. In 
this study, the accuracy rate of CNB is comparable 
with the open biopsy as gold standard. To improve 
accuracy of CNB, deep discussion in CPC must be 
done. CPC significantly provides better accuracy 
rate of CNB. Immunohistochemistry is, an integral 
part of diagnostic process, able to increase the 
accuracy of CNB as well.
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